Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

@article{Chang1998PhaseIS,
  title={Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.},
  author={Susan M. Chang and John G. Kuhn and Jinee Rizzo and Hillary Robins and S. Clifford Schold and Alexander M. Spence and Mitchell S Berger and Minesh P. Mehta and Michael E. Bozik and Ian F Pollack and Mark R. Gilbert and Dorcas Fulton and Cathryn Rankin and Mary K. Malec and Michael D. Prados},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 6},
  pages={2188-94}
}
PURPOSE To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients. The starting dose was 240 mg/m2 administered intravenously with escalations of 30 mg/m2 until the MTD was established. Pharmacokinetic data were obtained for each patient for the first… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Materia Medica for Various Cancers

Evidence-based Anticancer Complementary and Alternative Medicine • 2012

Similar Papers

Loading similar papers…